The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...

Assenagon Asset Management S.A. raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 12.4% during the 4th quarter, HoldingsChannel reports. The fund owned 238,522 shares of ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...

Christopher Von Seggern stepped down as Chief Commercial Officer of Xenon Pharmaceuticals Inc. and departed from the company. In connection with his departure ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

For the mountaineers, climbing the peaks of Mount Everest is the piece de resistance of their careers. What a lot of people don't realize is that accomplishing ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

A group of mountaineers plan to travel from Heathrow to the summit of Mount Everest and back in just seven days - a feat ...

Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...

About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ...

International Isotopes Inc. ("International Isotopes," "INIS" or the "Company") is pleased to announce that it has amended ...

She is the co-founder of PowerZone Trading, a company that has provided programming, consulting, and strategy development services to active traders and investors since 2004. Diane Costagliola is ...